3 PMX presentations in Italy today, cardiac relatedSeems the reduction of endotoxin plays a meaningful role in both adult and pediactric patients. Toray is introducing their new filter for the pediactric market and discussion too around the use of PMX in cardiac transplant surgery. I remember the days of PMX being dicussed as an adjunctive therapy in transplant surgery...this was back in the day when the EAA was said to be a tool for, "ruling out gram negative infection"....times have changed, it was in this Spectraloetic Era that Dr. Walker would write a nice annual letter telling us all about the company advances...now we opine over the January presentation and wonder whether Cormark has removed the 3 cent target yet ; - ) ....The actual amount of FDA advancement must be much greater than the phase 4 TIGRIS 2:1 ratio in favor of the PMX theranostic approach suggests....
Bon appetitio\
Thome
PS - not all timelines are "hap-hazard" or missed by accident or otherwise...did you know our former CEO worked exactly 20 years to the day he arrived? ...and you kids wanted to throw us another late inning curve-ball ; - )